Our paper on mutations analysis in the Geparsixto TNBC-Arm was discussed at ASCO-News.
Effect of BRCA1/2 Status on Response to Neoadjuvant Carboplatin in Triple-Negative Breast Cancer
Our EDC MedCODES will be unavailable Feb 22nd until 25th.
ESMO Breast Cancer is an annual congress taking place on 2-4 May 2019 in Berlin, Germany.
Prof. Dr. Sibylle Loibl, CEO of the GBG Forschungs GmbH and Professor at the Goethe University Frankfurt is featured among these researchers in 2018 for her work in breast cancer research.
We are delighted to inform you that the results of an interim analysis from KATHERINE, a phase III open-labeled trial, have been published in the New England Journal of Medicine.
Further results from the prospective PANTHER trial focused on obese breast cancer patients treated with adjuvant tailored dose-dense chemotherapy versus standard treatment has been published in the Annals of Oncology.
GBG Forschungs GmbHMartin-Behaim-Str. 12 | 63263 Neu-Isenburg | Fax +49 6102 7480-440
+49 6102 7480-0 | nfGBGd